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Abstract— Multiple sclerosis (MS) affects the central ner-
vous system with a wide range of symptoms. MS can,
for example, cause pain, changes in mood and fatigue,
and may impair a person’s movement, speech and visual
functions. Diagnosis of MS typically involves a combination
of complex clinical assessments and tests to rule out other
diseases with similar symptoms. New technologies, such
as smartphone monitoring in free-living conditions, could
potentially aid in objectively assessing the symptoms of
MS by quantifying symptom presence and intensity over
long periods of time. Here, we present a deep-learning ap-
proach to diagnosing MS from smartphone-derived digital
biomarkers that uses a novel combination of a multilayer
perceptron with neural soft attention to improve learning of
patterns in long-term smartphone monitoring data. Using
data from a cohort of 774 participants, we demonstrate that
our deep-learning models are able to distinguish between
people with and without MS with an area under the receiver
operating characteristic curve of 0.88 (95% CI: 0.70, 0.88).
Our experimental results indicate that digital biomarkers
derived from smartphone data could in the future be used
as additional diagnostic criteria for MS.
Index Terms— Artificial neural networks, digital biomark-
ers, medical diagnosis, multiple sclerosis, explainability
I. INTRODUCTION
MULTIPLE sclerosis (MS) is a neurological disease thataffects around 2 million people worldwide [1]. The
neural lesions caused by MS reduce the capability of neurons
to transmit information, which leads to a wide range of symp-
toms, such as changes in sensation, mobility, balance, vision,
and cognition [2]. Diagnosing MS requires objective evidence
of two lesions in the central nervous system disseminated
both in time and space [3], [4]. Physicians typically use a
combination of clinical assessments of symptoms, blood tests,
imaging, cerebrospinal fluid analysis and analysis of evoked
potentials to rule out other diseases with similar symptoms [3],
[4], [5]. Currently, no cure exists for MS, but there are treat-
ments available that are effective at managing the symptoms
of MS and may significantly improve long-term outcomes [2],
[6], [7]. To receive early access to these treatments, a timely
diagnosis is of paramount importance for patients.
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Fig. 1. Smartphone-based tests (top) can be used to assess cognition,
movement and finger dexterity symptoms of multiple sclerosis (MS) and
track their progression over time. We train machine-learning models to
learn to produce a scalar diagnostic score y (bottom) from the data
collected during any number of those tests to learn to diagnose MS.
Smartphone-based tests could potentially be used to quan-
tify symptoms of MS in the wild over long periods of time
(Figure 1). However, to date, it has not been established
whether and to what degree smartphone monitoring data can
be used to derive digital biomarkers for the diagnosis of MS.
A particularly challenging aspect of using smartphone data
to derive digital biomarkers for the diagnosis of MS is that
smartphone monitoring yields large amounts of high-resolution
data from multiple symptom categories. Identifying the salient
input segments and reaching a clinically meaningful conclu-
sion from raw sensor data in an accurate and timely manner
is therefore challenging both for physicians and machines.
To address these issues, we present a machine-learning
approach for distinguishing between people with and without
MS from smartphone data. At its core, our method uses an
attentive aggregation model (AAM) that integrates the results
of multiple tests over time to produce a single diagnostic
score. By integrating neural attention in our model, we are
additionally able to quantify the importance of individual tests
towards the model’s output. Our experiments on real-world
smartphone monitoring data show that our method outperforms
several strong baselines, identifies meaningful patterns, and
that smartphone data could potentially be used to derive digital
biomarkers for the diagnosis of MS.
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Concretely, our contributions are as follows:
• We present a deep-learning approach to distinguishing
between people with and without MS that integrates data
from multiple types of smartphone-based tests performed
over long time frames (up to more than 200 days).
• We extend our deep-learning approach with neural soft
attention in order to quantify the importance of individual
input features towards the final diagnostic score.
• We utilise real-world smartphone monitoring data from
774 subjects to evaluate, for the first time, the compara-
tive performance of machine-learning models and several
strong baselines in distinguishing between people with
and without MS.
II. RELATED WORK
Using machine learning to aid in medical tasks has attracted
much research interest. Researchers have, for example, used
machine learning for mortality modelling [8], sepsis decision
support [9], alarm reduction in critical care [10], to provide
explainable decisions in medical decision-support systems
[11], [12], [13], and to identify subtypes in autism spectrum
disorders [14] and scleroderma [15]. Giving a reliable diag-
nosis is one of the most challenging tasks in medicine that
requires significant domain knowledge in the disease being
assessed, and the ability to integrate information from a large
number of potentially noisy data sources. Machine learning
is an attractive tool to perform automated diagnoses because
it can draw upon the experience of millions of historical
samples in its training data, and seamlessly integrate data
from multiple disparate data sources. In previous studies,
machine learning has, for example, been used to diagnose
skin cancer from image data [16], glaucoma from standard
automated perimetry [17], and a large number of diseases
from electronic health records [18], [19] and lab test results
[20]. However, obtaining objective data about symptoms and
symptom progression over time is challenging in many dis-
eases. For some diseases, wearable devices and smartphones
have emerged as viable tools for gathering diagnostic data in
the wild. Smartphones and telemonitoring have, for example,
been used to gather digital biomarkers for the diagnosis of
melanomas [21], bipolar disorder [22], cognitive function [23],
and Parkinson’s disease [24], [25], [26], [27], [28]. The use of
machine learning on high-resolution health data often requires
specialised approaches to effectively deal with missingness
[29], [30], long-term temporal dependencies [19], noise [31],
heterogeneity [32], irregular sampling [18], sparsity [33], and
multivariate input data [10], [28], [34]. In this work, we build
on these advances to develop a novel approach to learning to
diagnose MS from smartphone-derived digital biomarkers that
addresses the aforementioned challenges.
A. Monitoring and Diagnosis of MS
The clinical state-of-the-art in monitoring symptoms and
symptom progression in MS is based on a combination of
clinical assessments, such as neurological exams, magnetic
resonance imaging (MRI), and the Expanded Disability Status
Scale (EDSS) [35], [36]. However, these tests can only be
performed at clinical centers by medical specialists. With
dozens of mHealth apps available to manage MS on all
major smartphone platforms, smartphone apps have recently
emerged as a readily accessible alternative to non-invasively
track symptoms of MS in the wild [37], [38]. Prior studies
on the use mHealth in MS have, for example, evaluated
telemedicine-enabled remote EDSS scoring [39], measurement
devices for estimating walking ability [40] and fatigue [41],
and machine learning for assessing gait impairment in MS
[42]. Epidemiologically, demographic factors, such as age and
sex, have been shown to be predictive of MS [43].
In contrast to existing works that focused on single daily-
life aspects of already diagnosed MS patients, we present an
approach to diagnosing MS from smartphone-derived digital
biomarkers, and verify this approach on a real-world dataset
collected from a MS cohort. Our machine-learning approach
addresses multiple challenges in learning from sensor-based
smartphone tests that are self-administered multiple times
over long periods of time. Most notably, with the integration
of a global neural soft attention mechanism, we enable the
quantification of the importance of individual smartphone tests
towards the final diagnostic score, overcome the challenges
of missingness, sparse data, long-term temporal dependencies
between tests, and multivariate data with irregular sampling.
III. METHODS AND MATERIALS
A. Smartphone Tests
We utilise data collected by the Floodlight Open study, a
large smartphone-based observational study for MS [44], [45].
The de-identified dataset used in this work is openly available
to researchers1. In the study, participants were asked to actively
perform a number of smartphone-based tests on a daily basis
using their personal smartphones in the wild and without any
clinical supervision (Figure 1). However, participants were free
to choose when and if they performed the daily tests. Many
participants therefore did not strictly adhere to the daily test
protocol, and performed the tests irregularly. In addition to the
manual tests, the app also passively collected movement data
of the participants in order to determine their radius of living.
The following tests were included in the study (Figure 1) [44]:
 Mood Questionnaire. In the mood questionnaire, partic-
ipants were asked a single question about their current
well-being. The answers were mapped to a scalar mood
score that was recorded for each answer. The score was
used to track changes of participants’ mood over time.
1 3 Symbol Matching. In the symbol matching test, par-
ticipants were presented with a mapping of symbols to
numbers. Participants were then prompted with a single
symbol from this mapping, and asked to translate the
shown symbol into the corresponding number using an
on-screen virtual keyboard. Once the user entered their
response, a new symbol would be shown. The goal was to
translate the presented symbols as quickly and accurately
as possible in a fixed amount of time. As metrics, the
average response time and the number of correct re-
sponses were recorded. There was also a baseline version
1https://floodlightopen.com
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of this test in which participants simply had to input
the presented numbers directly without any intermediate
mapping for which the same metrics were recorded.
 Walking. In the walking test, participants were asked
to take a walk for two minutes, where ever they saw
fit. Their smartphones recorded the number of steps
taken during this walk in order to capture whether the
participants’ ability to walk was impaired.
 U-turn. In the U-turn test, participants were asked to
walk as quickly as possible between two fixed points of
their choice that should approximately have been four
meters apart. Their smartphones recorded the number of
turns and the average turn speed during this test in order
to assess the participants’ ability to turn.
Balance. In the balance test, participants were asked to
stand still and hold their balance for a fixed amount of
time. The app recorded their postural sway during this
test in order to evaluate to what degree the participant
was able to remain still. Impaired postural control and
an increased risk of falling are symptoms commonly
associated with MS [46].
Mobility. The mobility test recorded the daily life space
of the participant using their smartphone’s location sen-
sors. The mobility test was the only test that ran in the
background and did not have to be manually activated.
Pinching. In the pinching test, participants were pre-
sented with a series of virtual objects in varying locations
on their smartphone screens. The participants were then
asked to perform a pinching gesture using their fingers
to squash the objects as quickly as possible. The app
recorded the number of successfully squashed objects
over a fixed amount of time, and which hand was used
to perform the pinching gesture. The aim was to measure
the participants’ pinching ability which may be impaired
in people with MS [47].
 Drawing. In the drawing test, participants were asked
to draw a sequence of shapes that was shown on their
screens using their fingers - twice for each shape. The
shapes represented a square, a circle, a figure eight,
and a spiral. For each shape, the app recorded the best
Hausdorff distance between the drawn and shown shapes.
B. Problem Statement
We consider the setting in which we are given a number k of
tests, including test scores si ∈ R, the time since the last test
ti in seconds, a one-hot encoded representation mi ∈ {0, 1}
of the test metric type with i ∈ [0 . . k− 1], and demographic
data d = (d0.d1), including age d0 ∈ N0 and sex d1 ∈ {0, 1},
of the participant that performed the tests. Our goal is to train
a predictive model P that produces a scalar diagnostic score
y ∈ [0, 1] that indicates the likelihood of the given set of test
results belonging to a participant with or without MS.
y = P ([0, t1, ..., ti], [m0, ...,mi], [s0, ..., si], d). (1)
The primary challenge in this setting is to identify predictive
patterns among the potentially large set of tests performed
irregularly over long periods of time that provide evidence for
or against a MS diagnosis.
C. Attentive Aggregation Model (AAM)
As predictive model P , we use an AAM - a deep-learning
model that utilises neural soft attention in order to integrate
information from a potentially large number of smartphone
test results. AAMs are based on evidence aggregation models
(EAMs) [28]. As a first step, we concatenate the time since
the respective prior test ti, result scores si, and test metric
indicators mi from the smartphone tests into k features xi.
xi = concatenate(ti,mi, si) (2)
We then use a multilayer perceptron (MLP) with a config-
urable number L of hidden layers and N neurons per hidden
layer to process each input feature into a N -dimensional high-
level hidden feature representation hi.
hi = MLP(xi) (3)
Next, we aggregate the information from all k high-level
hidden representations into a single aggregated hidden rep-
resentation hall that reflects all available tests for a given
participant. To do so, we used a learned neural soft attention
mechanism that weighs the individual hidden representations
hi of each individual test instance by their respective impor-
tance ai towards the final diagnostic output score.
hall =
∑k
i=1aihi (4)
Following [13], [31], [48], we calculate the attention factors
ai by first projecting the individual hidden representations hi
into an attention space representation ui through a single-layer
MLP with a weight matrix W and bias b.
ui = activation(Whi + b) (5)
We finalise the calculation of the attention factors ai by
computing a softmax over the attention space representations
ui of hi using the most informative hidden representation umax.
W , b and umax are learned parameters and optimised together
with the other parameters during training [28].
ai = softmax(uTi umax) (6)
We then calculate the final diagnostic score y using a MLP
with one sigmoid output node on a concatenation of the
aggregated hidden state hall and the demographic data d.
The integration of demographic information to the top-level
MLP enables the model to adjust the final prediction y for
epidemiological risk factors [43], such as sex and age.
y = MLP(concatenate(hall, d)) (7)
AAMs rely solely on attention to aggregate test results over
time. Using attention to perform the temporal aggregation has
the advantage that attention mechanisms learn global input-
output relations without regard to their distance in the input
sequence, and in this manner improve learning of long-range
temporal dependencies [49]. While global attention models are
commonly employed in natural language processing [49], [50],
we are not aware of any prior works that apply global attention
to improve learning of long-term temporal dependencies on
smartphone sensor data.
4 ARXIV PREPRINT
TABLE I
POPULATION STATISTICS. Training, validation, and test fold statistics.
Age and Usage are medians (10% and 90% quantiles in parentheses).
Property Training Validation Test
Subjects (#) 542 (70%) 77 (10%) 155 (20%)
MS (%) 51.9 52.0 51.6
Female (%) 60.3 59.7 60.7
Age (years) 41.0 (27.0, 59.0) 41.0 (26.5, 56.5) 41.0 (28.0, 57.5)
Usage (days) 22.4 (0.6, 203.5) 19.0 (0.8, 175.5) 18.8 (1.0, 130.0)
IV. EXPERIMENTS
To evaluate the predictive performance of AAMs in diagnos-
ing MS from smartphone data, we performed experiments that
compared the diagnostic performance of AAMs and several
baseline models on real-world smartphone monitoring data.
Our experiments aimed to answer the following questions:
1 What is the predictive performance of AAMs in diag-
nosing MS from smartphone data?
2 What is the predictive performance of AAMs compared
to other methods, such as Mean Aggregation and the
demographic baseline?
3 Which test types were most informative for diagnosing
MS, and to what degree?
4 To what degree does including more tests performed by
subjects improve predictive performance of AAMs?
5 Does the neural attention mechanism identify meaning-
ful patterns?
A. Dataset and Study Cohort
We used data from the Floodlight Open study that recruited
participants via their personal smartphones in, among others,
the United States (US), Canada, Denmark, Spain, Italy, the
Czech Republic, and Switzerland [44], [45]. To perform our
experimental comparison, we used all of the available smart-
phone monitoring data from April 23rd 2018 to August 29th
2019. In addition to regularly performing the smartphone-
based tests, participants also provided their demographic pro-
files upon sign-up. The demographic profile included age, sex,
and whether or not they had an existing diagnosis of MS.
To ensure that a minimal amount of data points are available
for diagnosis, we excluded all participants that had produced
fewer than 20 test results during the analysed time frame (312
participants). We chose the cutoff at a minimum of 20 tests
as this corresponds roughly to two sets of the daily test suite,
which would be the minimal amount of data needed to assess
symptom progression over time. We assigned the included
patients to three folds for training (70%), validation (10%) and
testing (20%) randomised within strata of diagnostic status,
app usage, sex, age, and number of tasks performed (Table I).
The training, validation and test folds were respectively solely
used for training, hyperparameter optimisation, and model
evaluation. On average, participants with MS performed more
tests over their app usage duration than participants without
MS - presumably because of their intrinsic motivation to better
understand their disease and help advance biomedical research.
B. Models
We trained a demographic baseline model, a Mean Aggre-
gation baseline, and several ablations of AAMs. The AAMs
used a fully-connected neural network as their base, and a
single neuron with a sigmoid activation function as output.
We trained one AAM version that received the demographic
information (AAM + age + sex), and one that did not (AAM).
For computational reasons, we limited the maximum number
of test results per participant. To estimate the performance
benefit of having access to information from more tests in the
analysis, we trained AAMs and Mean Aggregation using up
to the first 25, 30, 40, 50, 100, 150, 200, 250, 300 and 350
test results per participant, if available. For the demographic
baseline, we used a random forest (RF) model that received
as input only the age and sex of the participant (Age + sex).
We used the demographic baseline to evaluate whether and to
what degree data from the smartphone-based tests improves
predictive performance, since the demographic baseline only
had access to demographic data and did not include data from
the smartphone-based tests. As a simple reference baseline,
the Mean Aggregation utilised the mean normalised test result
score to produce the final diagnostic score - this served to de-
termine whether the use of more complex, learned aggregation
methods, such as AAMs, is effective and warranted.
C. Hyperparameters
To ensure all models were given the same degree of hy-
perparameter optimisation, we used a standardised approach
where each model was given an optimisation budget of 50
hyperparameter optimisation runs with hyperparameters cho-
sen from pre-defined ranges (Table II). The best performing
configuration on the validation fold was selected for further
evaluation. For the demographic baseline model, we used a RF
with T trees and a maximum tree depth of D. For the AAMs,
we used an initial MLP with L hidden layers, N hidden units
per hidden layer, a dropout percentage of p between hidden
layers, and an L2 weight penalty of strength s. We trained
AAMs to optimise binary cross entropy for a maximum of
300 epochs with a minibatch size of B participants and a
learning rate of 0.003. In addition, we used early stopping
with a patience of 32 epochs on the validation fold.
TABLE II
HYPERPARAMETERS. Ranges used for hyperparameter optimisation of
AAMs (top) and the Age + sex baseline using a Random Forest model
(RF, bottom). Parentheses indicate continuous ranges within the
indicated limits sampled at uniform probability. Comma-delimited lists
indicate discrete choices with equal selection probability.
Hyperparameter Range / Choices
A
A
M
Number of hidden units N 16, 32, 64, 128
Batch size B 16, 32, 64
L2 regularisation strength s 0.0001, 0.00001, 0.0
Number of layers L (1, 3)
Dropout percentage p (0%, 35%)
R
F Tree depth D 3, 4, 5
Number of trees T 32, 64, 128, 256
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TABLE III
PREDICTIVE PERFORMANCE. Comparison of Attentive Aggregation Models (AAMs), Mean Aggregation, and a demographic baseline (Age + sex)
in terms of AUC, AUPR, F1, sensitivity, and specificity for predicting MS on the test set using a maximum of 250 test results from each participant.
In parentheses are the 95% confidence intervals (CIs) obtained via bootstrap resampling. †= significant at p < 0.05 to AAM + age + sex.
Model (max. 250 test results) AUC AUPR F1 Sensitivity Specificity
AAM + age + sex 0.88 (0.70, 0.88) 0.90 (0.67, 0.90) 0.80 (0.65, 0.83) 0.83 (0.59, 0.86) 0.73 (0.62, 0.89)
Mean Aggregation + age + sex †0.77 (0.70, 0.82) †0.76 (0.64, 0.84) †0.71 (0.65, 0.78) †0.68 (0.59, 0.85) †0.75 (0.59, 0.87)
Age + sex †0.76 (0.69, 0.84) †0.75 (0.65, 0.86) †0.69 (0.62, 0.79) †0.73 (0.55, 0.83) †0.61 (0.58, 0.89)
AAM †0.72 (0.56, 0.82) †0.67 (0.57, 0.84) †0.61 (0.53, 0.77) †0.63 (0.45, 0.79) †0.83 (0.53, 0.86)
Mean Aggregation †0.56 (0.50, 0.67) †0.61 (0.49, 0.74) †0.39 (0.20, 0.54) †0.28 (0.13, 0.43) †0.85 (0.70, 0.97)
D. Preprocessing
We normalised the time between two test results ti to the
range [0, 1] using the highest observed ti on the training fold of
the dataset. We additionally normalised all test result scores xi
to the range of [0, 1] using the lowest and highest observed test
result for each test metric on the training fold of the dataset.
E. Metrics
1) Predictive Performance: We evaluated all models in terms
of their area under the receiver operating characteristic curve
(AUC), the area under the precision recall curve (AUPR),
and F1 score on the test fold of 155 participants. For the
comparison of predictive performance, we additionally com-
puted the sensitivity and specificity of the respective models.
We also quantified the uncertainty of all the performance
metrics by computing 95% confidence intervals (CIs) using
bootstrap resampling with 1000 bootstrap samples. To assess
the statistical significance of our results, we applied Mann-
Whitney-Wilcoxon (MWW) tests at significance level α =
0.05 to the main comparisons. We additionally applied the
Bonferroni correction to adjust for multiple comparisons.
2) Importance of Test Types: To quantify the importance of
the various test types toward the diagnostic performance of the
AAM, we retrained AAMs with the same hyperparameters af-
ter removing the test results from exactly one type of test. The
reduction in predictive performance associated with removing
the information of one test type can be seen as a proxy for
the importance of that test type [13], [51], since features that
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Fig. 2. Performance comparison of AAM (dots, blue) and Mean Ag-
gregation (triangles, orange) in terms of their Area Under the Precision-
Recall Curve (AUPR, y-axis) when varying the maximum number of test
results (x-axis) available to predict the MS diagnosis for each participant.
*** = significant at p < 0.001.
are associated with a higher reduction in prediction error carry
more weight in improving the model’s ability to predict MS.
3) Neural Attention: In order to qualitatively inspect the
patterns that were captured by the AAM in the data, we
additionally plotted the attention assigned to the test results
from a sample participant with MS over time.
V. RESULTS
A. Predictive Performance
In terms of predictive performance for diagnosing MS, the
AAMs models with demographic information (AAM + age +
sex) achieved a significantly (p < 0.05) higher AUC, AUPR
and F1 than all the baselines we evaluated (Table III). In
particular, we found that integrating the information from the
smartphone tests was crucial, as AAMs that used both the
demographic data and the smartphone test information sig-
nificantly (p < 0.05) outperformed the demographic baseline
(Age + sex) in terms of AUC, AUPR, and F1. Mean Ag-
gregation had a considerably lower performance than AAMs,
and displayed the worst AUC, AUPR and F1 of the compared
models - demonstrating that the use of more sophisticated
adaptive aggregation models for integrating information from
smartphone-based tests over time, such as AAMs, is effective
and warranted. We also found that AAMs achieved a high level
of both sensitivity and specificity, whereas the demographic
model emphasised sensitivity, and Mean Aggregation speci-
ficity. As expected, the AAM achieved a significantly higher
performance when it had access to demographic information,
as it was able to adjust for demographic risk factors by, for
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Fig. 3. Performance comparison of AAM in terms of their F1 score (y-
axis) in predicting the MS diagnosis for each participant after removal of
the information of all tests of a specific type (labelled test types, bottom)
from the dataset. The reference baseline without removal of any test
types (All Tests) is highlighted in orange. *** = significant at p < 0.001.
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*
Fig. 4. A set of test results as performed by a female participant (FL51683656) aged 49 with MS from the test set. The timeline depicts usage days
from earlier (left) to later (right). The black dots indicate that at least one test was performed that day. The absence of a dot indicates that no test
was performed that day. Symbols connected to marked days depict which tests were performed (Figure 1). The blue bars directly adjacent to the
symbols show how much total attention was assigned to that test instance. Total attention refers to the sum of attention assigned to all test results
belonging to a test instance, e.g. the Hausdorff distances for all shapes in a drawing test. We found that the model focused predominantly on the
mood, symbol matching, and drawing tests (* marks top 5 tests) to correctly identify (score = 0.77, threshold = 0.49) that this participant has MS.
example, assigning higher risk to female app users - which
have an up to three times higher MS risk than men [43].
B. Impact of Performing More Tests
The results from comparing AAMs and Mean Aggregation
in terms of their AUPR across a wide range of numbers of
test results indicated that AAMs are better able to leverage
an increasing number of tests performed (Figure 2). In terms
of predictive performance as measured by the AUPR, the
AAM surpassed the Mean Aggregation baseline at all eval-
uated maximum numbers of test results. We also found that
having access to a higher number of tests consistently and
significantly (50 vs. 100 test results, p < 0.001) improved the
performance of AAMs up to a maximum of 250 test results
per participant. Our results indicate that a respectable level of
predictive performance could be achieved after collecting just
100 test results. In practice, data collection could for example
be initiated upon referral to a specialist clinic or between
the first clinical contact and the diagnostic appointment. We
note that the time required to collect 100 test results is small
in relation to the median time between symptom onset and
diagnosis, which may be over two years in some countries
[52]. In addition, Floodlight Open tests have been reported to
be well accepted by patients with good adherence and patient
satisfaction over a monitoring period of 24 weeks [45].
C. Importance of Test Types
When comparing the marginal reduction in prediction error
associated with removing a specific type of test from the set
of available tests, we found that the drawing and mood tests
were contributing significantly larger marginal reductions (p <
0.001) in prediction error to the AAM (Figure 3) - indicating
that the drawing and mood tests were more predictive of
MS diagnosis than other test types. The removal of other
test types did not lead to similarly considerable reductions
in prediction error compared to the AAM that had access to
information from all test types (All Tests). This result could
indicate that the results of other test types were either (i) not
highly predictive of MS, or (ii) correlated with other tests to
a degree that strongly impacted their marginal contributions.
Further prospective studies will be necessary to determine
the optimal set of tests because confounding factors, such
as different usage patterns in response to different test suites
being available, may also influence predictive performance.
D. Neural Attention
Qualitatively, on the data from one sample participant, we
found that the model focused on mood, drawing, and symbol
matching tests to diagnose MS (Figure 4). The focus on mood
and drawing tests for this subject are in line with our findings
on the overall importance of the test types (Table 3).
VI. DISCUSSION
To the best of our knowledge, this work is the first to
present a machine-learning approach to diagnosing MS from
long-term smartphone monitoring data collected outside of the
clinical environment. To derive a scalar diagnostic score for
MS from smartphone monitoring data, we used an AAM to
aggregate data from multiple types of tests over long periods of
time. The AAMs used neural attention to quantify the degree to
which individual tests contribute to the final diagnostic score,
and to overcome the challenges of missingness, sparse data,
long-term temporal dependencies and irregular sampling. Our
experimental results indicate that AAMs outperform several
strong baselines, identify meaningful data points within the
set of performed tests, and that smartphone-based digital
biomarkers could potentially be used to aid in diagnosing MS
alongside existing clinical tests. Among the several potential
advantages of using smartphone-derived digital biomarkers
for diagnosing MS are that smartphone-based tests (i) can
be administered remotely and therefore potentially expand
access to underserved geographic regions, (ii) are inexpensive
to distribute and could therefore potentially become a low-cost
alternative to more expensive in-clinic tests, and (iii) are able
to integrate information from long-term symptom monitoring,
and therefore potentially better represent and quantify fluctu-
ations in symptom burden over time. An additional benefit of
using smartphone-based diagnostics for MS is that machine-
learning models can, as demonstrated in this work, identify
which symptom categories are most indicative of MS and how
they interact over time, and could therefore potentially be used
to monitor disease progression and inform follow-up treatment
decisions. Finally, our results show that information from
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Fig. 5. Comparison of the receiver operating characteristic (ROC)
curves of AAM + age + sex (black, dot), Age + sex (orange, triangle),
and Mean Aggregation + age + sex (blue, square) when using a
maximum of 250 test results to predict the MS diagnosis for each test set
participant. Symbols indicate the operating points (thresholds selected
on the validation fold) presented in the comparison in Table III.
smartphone-based biomarkers are to some degree orthogonal
to more traditional measurements, such as demographic data,
and could therefore potentially be integrated with information
from existing clinical tests and other multimodal data sources,
such as MRI, to further increase diagnostic accuracy.
A. Limitations
While of respectable size, the studied cohort was restricted
to residents of a limited number of countries and likely not
representative of the global population. More importantly, the
data originated from patients with a diagnosis at various stages
of the disease, instead of pre-diagnosis. Therefore, our work
cannot conclude whether people without clinical MS diagnosis
could be identified before they receive their diagnosis. A
prospective validation in a larger, clinically representative
cohort will be necessary to conclusively establish the per-
formance and utility of smartphone-derived biomarkers as a
tool to aid in the diagnosis of MS, and their robustness when
confronted with other disorders that have similar symptoms.
Further work should investigate whether such biomarkers are
also suitable to track disease progression, identify and predict
relapses, enable the effective tuning of therapeutic options and
medication dosages, enable earlier diagnoses, and eventually
also provide an accurate prognosis.
VII. CONCLUSION
We presented a novel machine-learning approach to dis-
tinguishing between people with and without MS based on
long-term smartphone monitoring data. Our method uses an
AAM to aggregate data from multiple types of tests over long
periods of time to produce a scalar diagnostic score. AAMs
use neural attention to quantify the degree to which individual
tests contributed to the diagnostic score, and to overcome
the challenges of missingness, sparse data, long-term tempo-
ral dependencies and irregular sampling. In an experimental
evaluation on smartphone monitoring data from a cohort of
774 people, we demonstrated that AAMs identify predictive
and meaningful digital biomarkers for diagnosing MS. Our
experiments show that smartphone-derived digital biomarkers
could potentially be used to aid in diagnosing MS in the
future alongside existing clinical tests. Smartphone-based tools
for tracking symptoms and symptom progression in MS may
improve clinical decision-making by giving clinicians access
to objectively measured high-resolution health data collected
outside the restricted clinical environment. In addition, our
solution based on attention mechanisms further elucidates the
basis of the model decisions and may enhance the clinician’s
understanding of the provided diagnostic score. We therefore
believe our initial results may warrant further research on how
digital biomarkers could be integrated into clinical workflows.
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